While most of us view them as the elephant in the

While most of us view them as the elephant in the room, big Pharma is not necessarily the enemy. They need small bio Pharma! They have chosen to abandon most of their traditional R&D and instead rely on acquisitions to replenish their pipelines and fuel sales. In 2009, 31% of all new drugs approved by the FDA were developed by small bio Pharma. Fast forward to 2018 and that number was 64%. And within the past five years, 63% of all new drugs approved by the FDA originated from small BP. As I see it, IP’s problem is not the commercial potential of their drugs, but the funds to run expensive trials. This is where big BP could really help.
As Drano said, it would have been preferential to move along to the P3 OM trial. But hindsight is 20/20 and now we have to play the hand we’ve been dealt. I like our science and still think that there is a possibility of funding (Gov. or BP). I’m anxious to see all of the internals from our P2 Covid trial and results of in vitro testing of Brilacidin against twenty other viruses.